1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Capital Allocation
INVESTOR
Jazz increased its 2022 guidance based on the strong uptake of Xywav (for narcolepsy and idiopathic hypersomnia) and Rylaze (for acute lymphoblastic leukemia), which have generated greater than expected prescriber and patient adoption. As a result, we’ve increased our fair value estimate to $187 per share from $172. We believe shares are currently trading at an attractive entry point in 4-star territory. We maintain our no-moat and negative trend ratings.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
